Neuromodulation to Overcome Severe Restless Legs Syndrome
Key facts
- Where
- Birmingham, United StatesSee the site
Where in United States
- UAB HospitalBirmingham, United StatesContact: Chris GonzalezNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Marshall Holland
- Trial code
- NCT07780032
- Record updated
- 9 October 2026
- Original description
This prospective, single-center, first-in-indication feasibility study will evaluate the safety and preliminary effectiveness of spinal cord stimulation (SCS) for the treatment of severe, treatment-refractory primary Restless Legs Syndrome (RLS). Participants will undergo implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System and will be followed for 24 months with clinical, neurophysiological, and patient-reported outcome assessments.Read full original descriptionShow less
Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
This prospective, single-center, first-in-indication feasibility study will evaluate the safety and preliminary effectiveness of spinal cord stimulation (SCS) for the treatment of severe, treatment-refractory primary Restless Legs Syndrome (RLS). Participants will undergo implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System and will be followed for 24 months with clinical, neurophysiological, and patient-reported outcome assessments.
Inclusion: Age >18 years and older; Received a medical diagnosis of RLS via first screening with Cambridge Hopkins- RLS questionnaire and confirmed via Hopkins-Hening Diagnostic questionnaire; IRLS Scale score ≥ 21 (classified as severe) and received a determination of treatment refractory RLS or inadequate response to standard medical treatment for RLS by a sleep medicine physician; RLS symptoms occur ≥ 3 nights per week; Willing and able to comply with study procedures; Able to provide informed consent.
Exclusion: Active medical implant in the body (i.e., pacemaker); History of prior SCS trial or implantation; Currently using another device to treat RLS; One or more of the following diagnoses: spinal cord injury or prior spinal surgery, severe peripheral neuropathy, severe psychiatric or cognitive disorder that may interfere with study participation, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e., Parkinson's disease), deep vein thrombosis, multiple sclerosis, known or suspected allergy to SCS materials; Other medical conditions that would put the subject at risk as determined by the investigators; HgA1C > 7.5 (excludes unstable diabetes melilitus); Age <18 years; Neuropathic pain, other than RLS on DN4 questionnaire; Any mental or physical limitation that would prevent completing and of the study protocols; Unable or unwilling to comply with study protocols; Pregnant, breastfeeding, or trying to become pregnant; Currently participating or plans to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigators, affect RLS; Ferritin < 50 ng/mL (excludes iron deficiency).